06 December 2015: Molecular Biology
Down-Regulation of miR-148a Promotes Metastasis by DNA Methylation and is Associated with Prognosis of Skin Cancer by Targeting TGIF2
Yanli Tian ABC , Wei Wei CDE , Li Li DE , Rongya Yang EFG
DOI: 10.12659/MSM.894826
Med Sci Monit 2015; 21:3798-3805
Abstract
BACKGROUND: MicroRNAs (miRNA) dysregulation has been considered to be significantly related to the occurrence and development of cancers. Several studies had proved that DNA methylation is an important cause of the abnormal expression of miRNAs. The purpose of this study was to investigate the methylation status of miR-148a and its effects on the metastasis and prognosis of skin cancer, as well as the interaction with TGIF2 gene.
MATERIAL AND METHODS: According to the qRT-PCR analysis, the expression of miR-148a was down-regulated in tumor tissues compared with the adjacent tissues and healthy controls (P<0.05). In vitro cell metastasis assay revealed that miR-148a could inhibit cell metastasis and its down-regulation promoted metastasis. Luciferase reporter assay found that TGIF2 gene was a target gene and its expression was suppressed by miR-148a in skin cancer.
RESULTS: Methylation-specific PCR demonstrated that DNA methylation rate of miR-148a was higher in tumor tissues than in adjacent tissues and healthy tissues (P<0.05). miR-148a expression was proved to be epigenetically regulated after the demethylation of it by 5-aza-20-deoxycytidine treatment and qRT-PCR analysis. miR-148a methylation was significantly influenced by many clinicopathologic characteristics such as age (P=0.000), pathological differentiation (P=0.000), and lymph node metastasis (P=0.000). Besides, Kaplan-Meier analysis showed patients with miR-148a methylation lived shorter than those without that (P<0.001). Cox regression analysis manifested that miR-148a methylation (HR=0.053, 95CI%=0.005–0.548, P=0.014) could be serve as an independent prognostic marker for skin cancer.
CONCLUSIONS: Taken together, the expression of miR-148a was regulated by DNA methylation and targeted by TGIF2. Its methylation may be a potential prognostic indicator in skin cancer.
Keywords: Epigenesis, Genetic, DNA Methylation, Homeodomain Proteins - genetics, MicroRNAs - genetics, Neoplasm Metastasis - genetics, RNA, Messenger - genetics, Repressor Proteins - genetics, Skin Neoplasms - pathology
Background
Skin cancers are one of the most common seen malignancies in human (1). Among them, non-melanoma skin cancer accounts for 10% of all cancer types and for less than 0.1% of cancer-related deaths [1,2]. The incidence of skin cancers has been increasing year by year and 2.75 million new cases in the worldwide annually [3,4]. Melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) are the main types of skin cancers [5]. And there are many risk factors for the incidence and development of skin cancer such as ultraviolet light exposure, age, male gender, genetic susceptibility, phenotypic features and immunity have been reported [6,7]. However, the pathogenesis of skin cancer has not been fully elucidated. Epigenetic alterations in multiple genes are believed to play crucial roles in skin carcinogenesis. The study of the fundamental mechanism of DNA methylation may be helpful to understand the progression of skin cancer.
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules with a length of 18–25 nucleotides. They have been confirmed to be related to progression of various cancers via acting as an oncogene or tumor suppressor and other roles. miRNAs also can regulate gene expression by specific sites within the 3′-Untranslated Regions (3′-UTR) of a target-mRNA at post transcriptional level [8]. Besides, they participate in many processes of diseases such as cell growth, cell cycle, apoptosis, migration and invasion [9]. The deregulated of miRNAs haven been confirmed to play vital role in various disease including cancers in previous studies.
In this study, we investigated the expression level of
Material and Methods
PATIENTS AND SAMPLES:
The current study was conducted in The General Hospital of Beijing Military Command and was permitted by the Ethics Committee of the hospital. 105 patients diagnosed as skin cancer were included. All the patients had never received any chemical treatment and physical therapy before sampling. Besides, 89 healthy people were taken as normal controls. Written informed consents were signed by each participator in advance.
Tumor tissues, adjacent tissues, and healthy tissues were collected from the patients with skin cancer and healthy people, respectively. Liquid nitrogen was used to immediately freeze the samples. Then the samples were stored at −80°C for later use. Clinicopathologic characteristics, such as age, sex, tumor thickness, tumor subtype, pathological differentiation, lymph node metastasis, and clinical stage, were recorded in a database. The follow-up was performed with a telephone interview or questionnaire for 5 years. The overall survival was defined as the day of surgery to the day of death. Patients who died from unexpected events or other diseases were excluded in our study.
QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QRT-PCR):
Total RNA was extracted from the patients with skin cancer and healthy controls with TRIzol (Invitrogen, Carlsbad, CA, USA). The reverse transcription was made to synthesize the first chain of cDNA with TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Then RT-PCR reaction was performed in the Applied Biosystems 7900 Fast Real-Time PCR system (Applied Biosystems, Foster City, California, USA).
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA):
Total protein was isolated from the tumor tissues, adjacent normal tissues, and healthy tissues. Then the levels of TGIF2 were determined by a commercial reagent kit following the manufacturer’s instructions.
LUCIFERASE REPORTER ASSAYS:
The wild- or mutant-type 3′-UTR of TGIF2 was inserted into the pcDNA3.1/HisC vector (Invitrogen, Carlsbad, CA). Cells were seed in 24-well plates for 24 h before transfection. Then the cells were transfected with the reporter vector (pcDNA3.1/HisC-TGIF2-WT-3′UTR or pcDNA3.1/HisC-TGIF2-MT-3′UTR) and
LENTIVIRUS INFECTION AND SIRNAS:
Lentiviruses containing
CELL CULTURE AND CELL METASTASIS ASSAYS:
Human skin cancer cell lines A431 were obtained from the Pasteur institute of Iran and cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. The mediums were maintained at 37°C in a humidified atmosphere containing 5% CO2. Cell metastasis was assessed by wound-healing assay. A confluent cell monolayer without FBS was scratched artificially using sterile tips, and wound-healing images were taken at 24 and 48 h later.
DNA EXTRACTION AND BISULFITE MODIFICATION:
Genomic DNA was extracted from the tumor tissues, adjacent tissues and healthy controls with the DNA Mammalian Genomic Purification Kit purchased from Sigma-Aldrich Co. (St. Louis, MO). Then the DNA was treated with sodium bisulfite using the EZ DNA Methylation TM Kit (Zymo Research, Orange, CA) to conduct the conversion of cytosine to uracil. The modified DNA was resuspended in elution buffer and stored at −20°C.
METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION (MSP):
The modified DNA was used to analyze the methylation status of
5-AZA-DC TREATMENT:
To analyze the influence of
Results
THE DOWN-REGULATED OF MIR-148A IN PATIENTS WITH SKIN CANCER AT MRNA LEVEL:
The expression of miR-148a was detected by qRT-PCR at the mRNA level. The result demonstrated that its expression was significantly lower in tumor tissues than in adjacent normal tissues and healthy tissues (Figure 1, P<0.05). This revealed that miR-148a is a tumor suppressor in skin cancer.
MIR-148A INHIBITS THE CELL METASTASIS:
To further understand the function of miR-148a in skin cancers, we made a wound-healing assay to estimate its effects on cell metastasis. The outcome proved that the down-regulation of miR-148a induced the metastasis of skin cancer cells compared to the controls (Figure 2). In contrast, the cell metastasis was inhibited when the endogenous miR-148a was silenced. These results suggest that miR-148a might function as a tumor suppressor by promoting cell metastasis in skin cancer cells.
:
To elucidate the molecular mechanism by which miR-148a exerts its inhibitory effect on skin cancer cells, we measured the expression of TGIF2 which was predicted as potential targets of miR-148a. ELISA assay showed that the expression of TGIF2 protein was down-regulated in tumor tissues compared with those in adjacent tissues and healthy tissues (Figure 3, P<0.05). Then, we estimated the correlation between the expression of miR-148a and TGIF2, a positive correlation was shown (Figure 4). A luciferase reporter assay was further performed to verify whether miR-148a directly targets TGIF2 gene in skin caner cells. The wild-TGIF2 and mutant-TGIF2 containing the predicted binding sites of miR-148a were constructed and cloned downstream to a luciferase reporter, respectively. Then these two vectors were co-transfected with miR-148a mimics, miR-148a inhibitor (anti-miR-148a mimics), or their respective scrambled controls into A431 cells. The result indicated that transfection of miR-148a mimics significantly decreased the luciferase activity of cells (Figure 5). Moreover, the luciferase activity which was mediated by miR-148a was suppressed by the mutant putative binding sites. These findings support the hypothesis that TGIF2 is a direct target gene for miR-148a in skin cancer cells.
:
The TGIF2 was knocked-down to analyze its function in skin cancer by TGIF2-specific small interfering RNAs (si-TGIF2) and was confirmed by ELISA (Figure 6A). Then we performed transwell assays with wound-healing assays, which clarified that knockdown of TGIF2 in skin cancer cells could significantly inhibit cell migration ability (Figure 6B). This effect was as same as the down-regulation of miR-148a.
THE EXPRESSION OF MIR-148A IS EPIGENETICALLY REGULATED BY DNA METHYLATION IN SKIN CANCER CELLS:
MSP was carried out to observe the methylation of miR-148a in skin cancer cells. The A431 cells were treated with 5-Aza-dC, a demethyltransferase inhibitor, showing that the expression of miR-148a was up-regulated after the 5-Aza-dC treatment compared with those without treatment). We found that DNA methylation in miR-148a frequently occurred in 85 tumor tissues (55 partially methylated and 30 completely methylated), while the adjacent tissues and healthy controls were all unmethylated (Figure 7). This suggests that epigenetic factors can affect the expression of miR-148a, and that DNA methylation might be an important mechanism in the function of miR-148a on skin cancer.
THE RELATIONSHIP BETWEEN MIR-148A METHYLATION AND CLINICOPATHOLOGIC CHARACTERISTICS:
the above assays showed that miR-148a methylation might be a participator of the development of skin cancer. Therefore, we estimated the relationship between miR-148a methylation and clinicopathologic characteristics to prove our inference. As shown in Table 1, age (P=0.000), pathological differentiation (P=0.000), and lymph node metastasis (P=0.000) were considered to be vital influential factors to the methylation of miR-148a, which provided strong support for our view above.
THE ASSOCIATION BETWEEN MIR-148A METHYLATION AND OVERALL SURVIVAL:
To make sure the prognostic value of miR-148a methylation in skin cancer, we concluded the follow-up information and analyzed its role in prognosis via Kaplan-Meier and Cox regression analysis, respectively. Kaplan-Meier analysis showed that the overall survival of patients with miR-148a methylation was shorter than in those without miR-148a methylation (Figure 8, log rank test, P<0.001). The clinicopathologic characteristics, such as tumor thickness (HR=0.359, 95CI%=0.150–0.861, P=0.022), lymph node metastasis (HR=0.364, 95CI%=0.086–0.810, P=0.020), and clinical stage (HR=0.417, 95CI%=0.186–0.935, P=0.034), were proved to be related to the prognosis of skin cancer as well as miR-148a methylation (HR=0.053, 95CI%=0.005–0.548, P=0.014) and they might be independent prognostic indicators in skin cancer (Table 2).
Discussion
Numerous reports had reported that miRNAs act as important regulator in about one-third of human coding genes at the post-transcription level and plays a crucial role in most tumor formation and development [21].
Epigenetic modifications are a main cause of abnormal gene expression, including some miRNAs [23–25]. The aberrant DNA methylation of miRNA plays a significant role in cancer progression [26,27]. To make determine the influential factors of the down-regulation of
Metastasis is responsible for 90% of deaths in patients with solid tumors, especially lymphatic route of metastasis [28–30]. Several miRNAs had been confirmed to be linked with the metastasis of tumors such as miR-10b, miR-373, miR-126 and miR-335 in some cancers [31–33].
To explore the function of methylation in
Conclusions
The expression of
References
1. Jemal A, Bray F, Center MM, Global cancer statistics: Cancer J Clin, 2011; 61; 69-90
2. de Giorgi V, Grazzini M, Gori A, ABO blood group and risk of cutaneous malignant melanoma: Eur J Cancer Prev, 2011; 20; 121-22, pmid: 21332097
3. Cihan YB, Baykan H, Kavuncuoglu E, Relationships between skin cancers and blood groups – link between non-melanomas and ABO/Rh factors: Asian Pac J Cancer Prev, 2013; 14; 4199-203, pmid: 23991976
4. Marcil I, Stern RS, Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis: Arch Dermatol, 2000; 136; 1524-30, pmid: 11115165
5. Xie J, Qureshi AA, Li Y, Han J, ABO blood group and incidence of skin cancer: PLoS One, 2010; 5; e11972, pmid: 20694147
6. Han J, Colditz GA, Hunter DJ, Risk factors for skin cancers: a nested case-control study within the Nurses’ Health Study: Int J Epidemiol, 2006; 35; 1514-21, pmid: 16943234
7. Baykan H, Cihan YB, Ozyurt K, Roles of white blood cells and subtypes as inflammatory markers in skin cancer: Asian Pac J Cancer Prev, 2015; 16; 2303-6, pmid: 25824754
8. Wang X, Wang ZH, Wu YY, Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPACs/miR-124/Egr1 pathway: Mol Neurobiol, 2013; 47; 373-81, pmid: 23054680
9. Bushati N, Cohen SM, microRNA functions: Annu Rev Cell Dev Biol, 2007; 23; 175-205, pmid: 17506695
10. Wang SH, Li X, Zhou LS, microRNA-148a suppresses human gastric cancer cell metastasis by reversing epithelial-to-mesenchymal transition: Tumour Biol, 2013; 34; 3705-12, pmid: 23873106
11. Li J, Song Y, Wang Y, MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells: Mol Cell Biochem, 2013; 380; 277-82, pmid: 23670799
12. Takahashi M, Cuatrecasas M, Balaguer F, The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer: PLoS One, 2012; 7; e46684, pmid: 23056401
13. Gailhouste L, Gomez-Santos L, Hagiwara K, miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells: Hepatology, 2013; 58; 1153-65, pmid: 23532995
14. Schultz NA, Andersen KK, Roslind A, Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer – five microRNAs in a prognostic index: World J Surg, 2012; 36; 2699-707, pmid: 22851141
15. Aydogdu E, Katchy A, Tsouko E, MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer: Carcinogenesis, 2012; 33; 1502-11, pmid: 22562546
16. Ma W, Zhang X, Chai J, Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma: Tumour Biol, 2014; 35; 12467-72, pmid: 25185654
17. Lujambio A, Calin GA, Villanueva A, A microRNA DNA methylation signature for human cancer metastasis: Proc Natl Acad Sci USA, 2008; 105; 13556-61, pmid: 18768788
18. Zhu A, Xia J, Zuo J, MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer: Med Oncol, 2012; 29; 2701-9, pmid: 22167392
19. Li HP, Huang HY, Lai YR, Silencing of miRNA-148a by hypermethylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma: Oncotarget, 2014; 5; 7610-24, pmid: 25277193
20. Hanoun N, Delpu Y, Suriawinata AA, The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis: Clin Chem, 2010; 56; 1107-18, pmid: 20431052
21. Yang Y, Huang JQ, Zhang X, Shen LF, MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation: Mol Cell Biochem, 2015; 404; 229-39, pmid: 25772485
22. Haflidadottir BS, Bergsteinsdottir K, Praetorius C, Steingrimsson E, miR-148 regulates Mitf in melanoma cells: PLoS One, 2010; 5; e11574, pmid: 20644734
23. Nguyen T, Kuo C, Nicholl MB, Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma: Epigenetics, 2011; 6; 388-94, pmid: 21081840
24. Datta J, Kutay H, Nasser MW, Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis: Cancer Res, 2008; 68; 5049-58, pmid: 18593903
25. Braconi C, Huang N, Patel T, MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes: Hepatology, 2010; 51; 881-90, pmid: 20146264
26. Jones PA, Baylin SB, The epigenomics of cancer: Cell, 2007; 128; 683-92, pmid: 17320506
27. Ellis L, Atadja PW, Johnstone RW, Epigenetics in cancer: targeting chromatin modifications: Mol Cancer Ther, 2009; 8; 1409-20, pmid: 19509247
28. Fidler IJ, The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited: Nat Rev Cancer, 2003; 3; 453-58, pmid: 12778135
29. Gupta GP, Massague J, Cancer metastasis: building a framework: Cell, 2006; 127; 679-95, pmid: 17110329
30. Jackson DG, Lymphatic markers, tumour lymphangiogenesis and lymph node metastasis: Cancer Treat Res, 2007; 135; 39-53, pmid: 17953407
31. Ma L, Teruya-Feldstein J, Weinberg RA, Tumour invasion and metastasis initiated by microRNA-10b in breast cancer: Nature, 2007; 449; 682-88, pmid: 17898713
32. Huang Q, Gumireddy K, Schrier M, The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis: Nat Cell Biol, 2008; 10; 202-10, pmid: 18193036
33. Tavazoie SF, Alarcon C, Oskarsson T, Endogenous human microRNAs that suppress breast cancer metastasis: Nature, 2008; 451; 147-52, pmid: 18185580
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






